Cranbury

PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

Retrieved on: 
Tuesday, November 8, 2022
Director, GLOBE, Private Securities Litigation Reform Act, Pharming, NCT, Cranbury, Food, Nasdaq, Board, ASCO, R, Cancer, SEC, Fast Track, Company, Drug development, Clinical trial, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, COVID-19, Medical imaging, Pharmaceutical industry, Cryptocurrency, Fine chemical, G&A

Initial Phase 1 data presented at the 2022 ASCO annual meeting demonstrated responses in patients across multiple solid tumor types with a p53 Y220C mutation.

Key Points: 
  • Initial Phase 1 data presented at the 2022 ASCO annual meeting demonstrated responses in patients across multiple solid tumor types with a p53 Y220C mutation.
  • On track to initiate Phase 1b trial evaluating PC14586 in combination with KEYTRUDA in Q4 2022.
  • As of September 30, 2022, PMV Pharma had$258.9 millionin cash, cash equivalents, and marketable securities, compared to $314.1 millionat December 31, 2021.
  • PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53.

PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights

Retrieved on: 
Tuesday, August 9, 2022
MSD, FDA, Merck Sharp & Dohme Federal Credit Union, ASCO, GLOBE, R, Private Securities Litigation Reform Act, Medical Affairs Bureau, SEC, Clinical trial, Arnold J. Levine, Cancer, Patient, Pembrolizumab, Roche, COVID-19, Company, Merck & Co., Bayer, Research, Fast Track, Cranbury, NCT, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Cryptocurrency, Fine chemical, Merck, G&A

CRANBURY, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc.(PMV Pharma Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the second quarter endedJune 30, 2022, and provided a corporate update.

Key Points: 
  • CRANBURY, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc.(PMV Pharma Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the second quarter endedJune 30, 2022, and provided a corporate update.
  • Initial data from the dose-escalation portion of the Phase 1/2 PYNNACLE study were featured in an oral presentation at the 2022 ASCO annual meeting.
  • As of June 30, 2022, PMV Pharma had$277.4 millionin cash, cash equivalents, and marketable securities, compared to$339.0 millionas ofJune 30, 2021.
  • PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53.

PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

Retrieved on: 
Monday, July 18, 2022
MSD, SEC, AACR, Patient, ASCO, Food and Drug Administration Amendments Act of 2007, Nasdaq, Safety, Pharmacokinetics, Association, Pembrolizumab, GLOBE, Food, Trial of the century, American Association for Cancer Research, Private Securities Litigation Reform Act, Immune system, Poster, COVID-19, Cranbury, Company, American Association, Cancer, Merck Sharp & Dohme Federal Credit Union, FDA, Merck & Co., Pharmaceutical industry, Merck

PMV Pharma will evaluate PC14586 in combination with KEYTRUDA as a separate arm of the companys ongoing Phase 1/2 PYNNACLE trial in patients with advanced solid tumors.

Key Points: 
  • PMV Pharma will evaluate PC14586 in combination with KEYTRUDA as a separate arm of the companys ongoing Phase 1/2 PYNNACLE trial in patients with advanced solid tumors.
  • This combination arm will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PC14586 in combination with KEYTRUDA in patients with advanced solid tumors harboring a p53 Y220C mutation.
  • Under the terms of the agreement, PMV Pharma will sponsor the trial and Merck will supply KEYTRUDA.
  • Our tumor-agnostic study provides compelling scientific rationale for exploring PC14586 in combination with KEYTRUDA in an effort to improve outcomes for more patients.

PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation

Retrieved on: 
Tuesday, June 7, 2022
Cranbury, ALT, QD, Company, Society, Nausea, Anemia, Fatigue, ORR, Food, Pharmacokinetics, Webcast, Food and Drug Administration Amendments Act of 2007, Cancer, ASCO, MTD, NCT, Nasdaq, Breast, Therapy, American Society of Clinical Oncology, FDA, Prostate, GLOBE, Patient, Assistant, Private Securities Litigation Reform Act, Review, Trial of the century, COVID-19, CDT, AST, SEC, Vomiting, Index (publishing), Clinical trial, Squamous cell carcinoma, University, MD Anderson Cancer Center, RECIST, Safety, Pharmaceutical industry, Medical imaging, Vaccine

PC14586 is a first-in-class precision oncology small molecule investigational therapy that selectively targets the p53 Y220C mutation in solid tumors.

Key Points: 
  • PC14586 is a first-in-class precision oncology small molecule investigational therapy that selectively targets the p53 Y220C mutation in solid tumors.
  • The data were featured in an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) annual meeting.
  • Responses were observed across six distinct tumor types including breast, endometrial, prostate, pancreatic, ovarian, and small cell lung cancer.
  • PC14586 is being developed for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation.

PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Thursday, May 26, 2022
Cancer, Company, Neoplasm, Private Securities Litigation Reform Act, Cranbury, Nasdaq, AUC, Webcast, Patient, Clinical trial, Society, MD Anderson Cancer Center, COVID-19, American Society of Clinical Oncology, University, Safety, ASCO, Mutation, NCT, SEC, CEO, GLOBE, Pharmaceutical industry, Medical imaging, Cmax

These initial data from our Phase 1/2 tumor agnostic study enrolled patients across multiple tumor types over a broad range of doses.

Key Points: 
  • These initial data from our Phase 1/2 tumor agnostic study enrolled patients across multiple tumor types over a broad range of doses.
  • PC14586 is a first-in-class precision oncology small molecule investigational therapy that selectively targets the p53 Y220C mutation in solid tumors.
  • We look forward to Dr. Dumbravas presentation of these data at ASCO and continuing to progress the PC14586 development program.
  • The event will feature a presentation by Dr. Dumbrava who will review the data presented at ASCO 2022.

PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights

Retrieved on: 
Tuesday, May 10, 2022
Molecule, COVID-19, ASCO, Private Securities Litigation Reform Act, Nasdaq, GLOBE, Company, Research, Synergy, Patient, Association, Clinical trial, American Association, Cranbury, American Association for Cancer Research, NCT, R, SEC, White blood cell, Cancer, Pharmaceutical industry, G&A

CRANBURY, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc.(Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the first quarter endedMarch 31, 2022,and provided a corporate update.

Key Points: 
  • CRANBURY, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc.(Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the first quarter endedMarch 31, 2022,and provided a corporate update.
  • As of March 31, 2022, PMV Pharma had$294.8 millionin cash, cash equivalents, and marketable securities, compared to$314.1 millionas ofDecember 31, 2021.
  • Research and development (R&D) expenses were$11.8 millionfor the quarter endedMarch 31, 2022compared to$7.5 millionfor the quarter endedMarch 31, 2021.
  • General and administrative (G&A) expenses were$6.8 millionfor the quarter endedMarch 31, 2022, compared to$4.2 millionfor the quarter endedMarch 31, 2021.

PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Wednesday, April 27, 2022
ASCO, Society, Clinical trial, Annual general meeting, COVID-19, Cranbury, Private Securities Litigation Reform Act, GLOBE, Patient, American Society of Clinical Oncology, NCT, Nasdaq, Company, SEC, Cancer, Medical imaging, Pharmaceutical industry

PC14586 is being developed for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation.

Key Points: 
  • PC14586 is being developed for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation.
  • For more information on the Phase 1/2 trial, refer to www.clinicaltrials.gov (NCT study identifier NCT04585750).
  • PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53.
  • The field of p53 biology was established by our co-founder Dr.Arnold Levinewhen he discovered the p53 protein in 1979.

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

Retrieved on: 
Tuesday, March 1, 2022
GLOBE, Board of directors, Board, Commercial Operating System (COS), Pharmacokinetics, Secondary research, PMV, Research, BRAF, COVID-19, Chief commercial officer, Company, Cranbury, Breast cancer, Clinical trial, Corporation, Private Securities Litigation Reform Act, Safety, G&A, CMC, Cancer, Protein, Array BioPharma, Senior, DNA, Pfizer, Leadership, R, Nasdaq, Patient, Doctor of Philosophy, SEC, Renal cell carcinoma, Medical imaging, Pharmaceutical industry, Fine chemical

Fourth Quarter 2021 and Corporate Highlights:

Key Points: 
  • Fourth Quarter 2021 and Corporate Highlights:
    Patient enrollment in the Phase 1 portion of the Phase 1/2 clinical trial of PC14586 continues in line with the Companys expectations.
  • The Company plans to disclose initial results from this study in the first half of 2022.
  • In addition to continuing work on its p53 mutant programs, PMV expands its pipeline by advancing WIP1 (Wild-Type p53-Induced Phosphatase) inhibitor program, into lead optimization.
  • PMV Pharma ended the fourth quarter with$314.1 millionin cash, cash equivalents, and marketable securities, compared to$361.4 millionas ofDecember 31, 2020.

Infragistics’ Reveal Named in 2021 Gartner® Market Guide for Embedded Analytics

Retrieved on: 
Wednesday, December 8, 2021
Cloud, SVP, Research, GLOBE, Technology, Publication, Government, Software, Apple Developer Tools, Embedded analytics, Intelligence, IOS SDK, Alibaba Cloud, IOS, Android, SDK, Solution, IBM, Embedded, Microsoft, Table, Mobile phone

For many companies, the ability to empower end users with easy-to-view data--rather than using outdated reporting methods such as displaying spreadsheets or having them manually request data--is what stands between them and ongoing user adoption and retention. By embedding business intelligence into their software applications, companies quickly add value to their apps and gain a competitive advantage over other options on the market. 

Key Points: 
  • Cranbury, NJ, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Reveal , the business intelligence SDK that enables software companies to transform data into embedded dashboards and visualizations within their applications, has been named as one of 31 Representative Vendors in 2021 Gartner Market Guide for Embedded Analytics.
  • 2021 Gartner Market Guide provides, Gartners initial coverage of the market and focuses on the market definition, rationale for the market and market dynamics.
  • Further Gartner adds, The vendors listed in its research were selected as a sample based on having embedded analytics offerings and pricing for embedded usage.
  • [1] Gartner, Market Guide for Embedded Analytics, James Richardson, Julian Sun, Kevin Quinn, 4 October 2021.

PARTS iD, Inc. Launches EV Specialty Shop on CARiD.com

Retrieved on: 
Tuesday, November 30, 2021
Ford Motor Company, Algorithm, Stock, Ford Mustang, Specialty store, CEO, Audi e-tron (2018), Environment, Technology, Time, Industry, Private Securities Litigation Reform Act, Company, NYSE, Ford Mustang Mach-E, EVS, SEC, Leadership, ID, Chevrolet, COVID-19, EV, Polestar 1, Intellectual property, Policy, Nissan Leaf, Porsche, GLOBE, E-commerce, U.S. Securities and Exchange Commission, Hyundai, Polestar, EMarketer, Maintenance, Growth, Ioniq, Porsche Taycan, Online shopping, Retail, Risk management

Creating a dedicated destination for EV parts and accessories is a key milestone in PARTS iDs efforts to penetrate the growing EV market and its broader mission to offer a one-stop shop for all automotive shoppers.

Key Points: 
  • Creating a dedicated destination for EV parts and accessories is a key milestone in PARTS iDs efforts to penetrate the growing EV market and its broader mission to offer a one-stop shop for all automotive shoppers.
  • Using PARTS iDs robust fitment data, EV shoppers can browse with confidence, inputting their vehicles make, model and year to identify the correct parts and have them delivered right to their door.
  • The launch of our EV Specialty Shop is an exciting accomplishment for our team.
  • With the introduction of a dedicated EV Shop, we are taking the lead by providing EV drivers with direct access to the parts and accessories they want.